NOT KNOWN FACTS ABOUT MIRTAZAPINE AND SUBUTEX

The concomitant use of buprenorphine and CYP3A4 inducers can lower the plasma concentration of buprenorphine [see CLINICAL PHARMACOLOGY], possibly causing reduced efficacy or onset of the withdrawal syndrome in clients who have produced Actual physical dependence to buprenorphine.In subjects with HCV infection but no signal of hepatic impairment, t